Targeting PI3K isoforms and SHIP in the immune system: New therapeutics for inflammation and leukemia

Current Opinion in Pharmacology

Volumn 12, Issue 4, 2012, Pages 444-451

  Blunt, Matthew D ^a   Ward, Stephen G ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 ALPHA AMINOCHOLESTANE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; AQX 016A; AQX 1125; AQX MN 100; BORTEZOMIB; CAL 263; ENZYME ACTIVATOR; ENZYME INHIBITOR; IPI 145; PELOROL; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE 1; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE 1 ACTIVATOR; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE 1 INHIBITOR; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE 2; SH2 DOMAIN CONTAINING INOSITOL 5 PHOSPHATASE 2 INHIBITOR; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC RHINITIS; ASTHMA; AUTOIMMUNE DISEASE; BASOPHIL; BONE MARROW CELL; DENDRITIC CELL; DRUG DEVELOPMENT; DRUG TARGETING; ENZYME INHIBITION; GENE TARGETING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATORY DISEASE; LEUKEMIA; MAST CELL; MOLECULAR SIZE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; LEUKEMIA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC MONOESTER HYDROLASES;

EID: 84865012034     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.02.015     Document Type: Review

References (69)

1. S.G. Ward, and F.M. Marelli-Berg Mechanisms of chemokine and antigen-dependent T-lymphocyte navigation Biochem J 418 2009 13 27
2. T. Crabbe, M.J. Welham, and S.G. Ward The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci 32 2007 450 456
3. B. Vanhaesebroeck, K. Ali, A. Bilancio, B. Geering, and L.C. Foukas Signalling by PI3K isoforms: insights from gene-targeted mice Trends Biochem Sci 30 2005 194 204
4. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, and B. Bilanges The emerging mechanisms of isoform-specific PI3K signalling Nat Rev Mol Cell Biol 11 2010 329 341
5. J. Guillermet-Guibert, K. Bjorklof, A. Salpekar, C. Gonella, F. Ramadani, A. Bilancio, S. Meek, A.J. Smith, K. Okkenhaug, and B. Vanhaesebroeck The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma Proc Natl Acad Sci USA 105 2008 8292 8297
6. M.C. Schmid, C.J. Avraamides, H.C. Dippold, I. Franco, P. Foubert, L.G. Ellies, L.M. Acevedo, J.R. Manglicmot, X. Song, and W. Wrasidlo Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kgamma, a single convergent point promoting tumor inflammation and progression Cancer Cell 19 2011 715 727
7. I. Alcazar, M. Marques, A. Kumar, E. Hirsch, M. Wymann, A.C. Carrera, and D.F. Barber Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation J Exp Med 204 2007 2977 2987
8. T.M. Randis, K.D. Puri, H. Zhou, and T.G. Diacovo Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils Eur J Immunol 38 2008 1215 1224
9. A. Saudemont, F. Garcon, H. Yadi, M. Roche-Molina, N. Kim, A. Segonds-Pichon, A. Martin-Fontecha, K. Okkenhaug, and F. Colucci p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease Proc Natl Acad Sci USA 106 2009 5795 5800
10. S.I. Gharbi, M.J. Zvelebil, S.J. Shuttleworth, T. Hancox, N. Saghir, J.F. Timms, and M.D. Waterfield Exploring the specificity of the PI3K family inhibitor LY294002 Biochem J 404 2007 15 21
11. E.H. Walker, M.E. Pacold, O. Perisic, L. Stephens, P.T. Hawkins, M.P. Wymann, and R.L. Williams Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol Cell 6 2000 909 919
12. A. Berndt, S. Miller, O. Williams, D.D. Le, B.T. Houseman, J.I. Pacold, F. Gorrec, W.C. Hon, Y. Liu, and C. Rommel The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors Nat Chem Biol 6 2010 117 124
13. Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, and B. Toth A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 125 2006 733 747
14. M. Camps, T. Rückle, J. Hong, V. Ardissone, F. Rintelen, J. Shaw, C. Ferrandi, C. Chabert, C. Gillieron, and B. Françon Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis Nat Med 11 2005 936 943
15. C. Sadhu, B. Masinovsky, K. Dick, C.G. Sowell, and D.E. Staunton Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement J Immunol 170 2003 2647 2654
16. B.J. Lannutti, S.A. Meadows, S.E. Herman, A. Kashishian, B. Steiner, A.J. Johnson, J.C. Byrd, J.W. Tyner, M.M. Loriaux, and M. Deininger CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
17. J. Hoellenriegel, S.A. Meadows, M. Sivina, W.G. Wierda, H. Kantarjian, M.J. Keating, N. Giese, S. O'Brien, A. Yu, and L.L. Miller The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood 118 2011 3603 3612
18. P. Norman Selective PI3Kdelta inhibitors, a review of the patent literature Expert Opin Ther Pat 21 2011 1773 1790
19. J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, and W. Wrasidlo Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3- hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease J Pharmacol Exp Ther 328 2009 758 765
20. J. Doukas, W. Wrasidlo, G. Noronha, E. Dneprovskaia, R. Fine, S. Weis, J. Hood, A. Demaria, R. Soll, and D. Cheresh Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury Proc Natl Acad Sci USA 103 2006 19866 19871
21. K.B. Boyle, D. Gyori, A. Sindrilaru, K. Scharffetter-Kochanek, P.R. Taylor, A. Mocsai, L.R. Stephens, and P.T. Hawkins Class IA phosphoinositide 3-kinase beta and delta regulate neutrophil oxidase activation in response to Aspergillus fumigatus hyphae J Immunol 186 2011 2978 2989
22. S. Kulkarni, C. Sitaru, Z. Jakus, K.E. Anderson, G. Damoulakis, K. Davidson, M. Hirose, J. Juss, D. Oxley, and T.A. Chessa PI3Kbeta plays a critical role in neutrophil activation by immune complexes Sci Signal 4 2011 ra23
23. J.E. Bird, P.L. Smith, J.S. Bostwick, P. Shipkova, and W.A. Schumacher Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-beta inhibitor in mice Thromb Res 127 2011 560 564
24. M.A. Lemmon, and K.M. Ferguson Signal-dependent membrane targeting by pleckstrin homology (PH) domains Biochem J 350 2000 1 18
25. S.J. Harris, R.V. Parry, J. Westwick, and S.G. Ward Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes J Biol Chem 283 2008 2465 2469
26. S. Keck, M. Freudenberg, and M. Huber Activation of murine macrophages via TLR2 and TLR4 is negatively regulated by a Lyn/PI3K module and promoted by SHIP1 J Immunol 184 2010 5809 5818
27. L.M. Sly, M.J. Rauh, J. Kalesnikoff, C.H. Song, and G. Krystal LPS-induced upregulation of SHIP is essential for endotoxin tolerance Immunity 21 2004 227 239
28. J.N. Gabhann, R. Higgs, K. Brennan, W. Thomas, J.E. Damen, N. Ben Larbi, G. Krystal, and C.A. Jefferies Absence of SHIP-1 results in constitutive phosphorylation of tank-binding kinase 1 and enhanced TLR3-dependent IFN-beta production J Immunol 184 2010 2314 2320
29. S.J. Harris, R.V. Parry, J.G. Foster, M.D. Blunt, A. Wang, F. Marelli-Berg, J. Westwick, and S.G. Ward Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility J Immunol 186 2011 4936 4945
30. N.R. Locke, S.J. Patterson, M.J. Hamilton, L.M. Sly, G. Krystal, and M.K. Levings SHIP regulates the reciprocal development of T regulatory and Th17 cells J Immunol 183 2009 975 983
31. E. Kuroda, F. Antignano, V.W. Ho, M.R. Hughes, J. Ruschmann, V. Lam, T. Kawakami, W.G. Kerr, K.M. McNagny, and L.M. Sly SHIP represses Th2 skewing by inhibiting IL-4 production from basophils J Immunol 186 2011 323 332
32. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
33. M.C. Hollander, G.M. Blumenthal, and P.A. Dennis PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nat Rev Cancer 11 2011 289 301
34. J.M. Luo, H. Yoshida, S. Komura, N. Ohishi, L. Pan, K. Shigeno, I. Hanamura, K. Miura, S. Iida, and R. Ueda Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia Leukemia 17 2003 1 8
35. J.M. Luo, Z.L. Liu, H.L. Hao, F.X. Wang, Z.R. Dong, and R. Ohno Mutation analysis of SHIP gene in acute leukemia Zhongguo Shi Yan Xue Ye Xue Za Zhi 12 2004 420 426
36. S. Costinean, S.K. Sandhu, I.M. Pedersen, E. Tili, R. Trotta, D. Perrotti, D. Ciarlariello, P. Neviani, J. Harb, and L.R. Kauffman Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice Blood 114 2009 1374 1382
37. P.S. Eis, W. Tam, L. Sun, A. Chadburn, Z. Li, M.F. Gomez, E. Lund, and J.E. Dahlberg Accumulation of miR-155 and BIC RNA in human B cell lymphomas Proc Natl Acad Sci USA 102 2005 3627 3632
38. G.K. Lakhanpal, L.M. Vecchiarelli-Federico, Y.J. Li, J.W. Cui, M.L. Bailey, D.E. Spaner, D.J. Dumont, D.L. Barber, and Y. Ben-David The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis Blood 116 2010 428 436
39. T. Ghansah, K.H. Paraiso, S. Highfill, C. Desponts, S. May, J.K. McIntosh, J.W. Wang, J. Ninos, J. Brayer, and F. Cheng Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses J Immunol 173 2004 7324 7330
40. S. Pilon-Thomas, N. Nelson, N. Vohra, M. Jerald, L. Pendleton, K. Szekeres, and T. Ghansah Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function PLoS ONE 6 2011 e27729
41. D.W. Lee, M. Futami, M. Carroll, Y. Feng, Z. Wang, M. Fernandez, Z. Whichard, Y. Chen, S. Kornblau, and E.J. Shpall Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155 Oncogene 2012 10.1038/onc.2011.579 [Epub ahead of print]
42. Y. Choi, J. Zhang, C. Murga, H. Yu, E. Koller, B.P. Monia, J.S. Gutkind, and W. Li PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells Oncogene 21 2002 5289 5300
43. R. Brooks, G.M. Fuhler, S. Iyer, M.J. Smith, M.Y. Park, K.H. Paraiso, R.W. Engelman, and W.G. Kerr SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells J Immunol 184 2010 3582 3589
44. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274
45. E. Charlier, C. Conde, J. Zhang, L. Deneubourg, E. Di Valentin, S. Rahmouni, A. Chariot, P. Agostinis, P.C. Pang, and S.M. Haslam SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity Leukemia 24 2010 821 832
46. L. Yang, D.E. Williams, A. Mui, C. Ong, G. Krystal, R. van Soest, and R.J. Andersen Synthesis of pelorol and analogues: activators of the inositol 5-phosphatase SHIP Org Lett 7 2005 1073 1076
47. C.J. Ong, A. Ming-Lum, M. Nodwell, A. Ghanipour, L. Yang, D.E. Williams, J. Kim, L. Demirjian, P. Qasimi, and J. Ruschmann Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells Blood 110 2007 1942 1949
48. M. Kennah, T.Y. Yau, M. Nodwell, G. Krystal, R.J. Andersen, C.J. Ong, and A.L. Mui Activation of SHIP via a small molecule agonist kills multiple myeloma cells Exp Hematol 37 2009 1274 1283
49. G.M. Fuhler, R. Brooks, B. Toms, S. Iyer, E.A. Gengo, M.Y. Park, M. Gumbleton, D.R. Viernes, J.D. Chisholm, and W.G. Kerr Therapeutic potential of SHIP1 and SHIP2 inhibition in cancer cells Mol Med 18 2012 65 75
50. W.G. Kerr Inhibitor and activator: dual functions for SHIP in immunity and cancer Ann N Y Acad Sci 1217 2011 1 17
51. L.M. Ooms, K.A. Horan, P. Rahman, G. Seaton, R. Gurung, D.S. Kethesparan, and C.A. Mitchell The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease Biochem J 419 2009 29 49
52. A. Suwa, T. Yamamoto, A. Sawada, K. Minoura, N. Hosogai, A. Tahara, T. Kurama, T. Shimokawa, and I. Aramori Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2 Br J Pharmacol 158 2009 879 887
53. F. Vandeput, L. Combettes, S.J. Mills, K. Backers, A. Wohlkonig, J.B. Parys, H. De Smedt, L. Missiaen, G. Dupont, and B.V. Potter Biphenyl 2,3′,4,5′,6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes FASEB J 21 2007 1481 1491
54. S.J. Mills, C. Persson, G. Cozier, L. Tresaugues, C. Erneux, A.M. Riley, B.V. Potter, P. Nordlund, and M.P. Thomas A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery ACS Chem Biol 7 2012 822 828 10.1021/cb200494d
55. C.E. Edling, F. Selvaggi, R. Buus, T. Maffucci, P. Di Sebastiano, H. Friess, P. Innocenti, H.M. Kocher, and M. Falasca Key role of phosphoinositide 3-kinase class IB in pancreatic cancer Clin Cancer Res 16 2010 4928 4937
56. J.A. Brazzatti, M. Klingler-Hoffmann, S. Haylock-Jacobs, Y. Harata-Lee, M. Niu, M.D. Higgins, M. Kochetkova, P. Hoffmann, and S.R. McColl Differential roles for the p101 and p84 regulatory subunits of PI3Kgamma in tumor growth and metastasis Oncogene 31 2012 2350 2361 10.1038/onc.2011.414 [Epub ahead of print]
57. M.J. Rauh, V. Ho, C. Pereira, A. Sham, L.M. Sly, V. Lam, L. Huxham, A.I. Minchinton, A. Mui, and G. Krystal SHIP represses the generation of alternatively activated macrophages Immunity 23 2005 361 374
58. J.B. Moon, J.H. Kim, K. Kim, B.U. Youn, A. Ko, S.Y. Lee, and N. Kim Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade J Immunol 188 2012 163 169
59. W.G. Kerr, M.Y. Park, M. Maubert, and R.W. Engelman SHIP deficiency causes Crohn's disease-like ileitis Gut 60 2011 177 188
60. Q. Peng, S. Malhotra, J.A. Torchia, W.G. Kerr, K.M. Coggeshall, and M.B. Humphrey TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1 Sci Signal 3 2010 ra38
61. J. Kalesnikoff, V. Lam, and G. Krystal SHIP represses mast cell activation and reveals that IgE alone triggers signaling pathways which enhance normal mast cell survival Mol Immunol 38 2002 1201 1206
62. T. Tarasenko, H.K. Kole, A.W. Chi, M.M. Mentink-Kane, T.A. Wynn, and S. Bolland T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses Proc Natl Acad Sci USA 104 2007 11382 11387
63. S. Bolland, R.N. Pearse, T. Kurosaki, and J.V. Ravetch SHIP modulates immune receptor responses by regulating membrane association of Btk Immunity 8 1998 509 516
64. S.K. O'Neill, A. Getahun, S.B. Gauld, K.T. Merrell, I. Tamir, M.J. Smith, J.M. Dal Porto, Q.Z. Li, and J.C. Cambier Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy Immunity 35 2011 746 756
65. E. Kuroda, V. Ho, J. Ruschmann, F. Antignano, M. Hamilton, M.J. Rauh, A. Antov, R.A. Flavell, L.M. Sly, and G. Krystal SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils J Immunol 183 2009 3652 3660
66. L.A. Kamen, J. Levinsohn, A. Cadwallader, S. Tridandapani, and J.A. Swanson SHIP-1 increases early oxidative burst and regulates phagosome maturation in macrophages J Immunol 180 2008 7497 7505
67. F. Antignano, M. Ibaraki, C. Kim, J. Ruschmann, A. Zhang, C.D. Helgason, and G. Krystal SHIP is required for dendritic cell maturation J Immunol 184 2010 2805 2813
68. F. Antignano, M. Hamilton, S. Patterson, V. Ho, C. Cohen, M.K. Levings, and G. Krystal SHIP-deficient dendritic cells, unlike wild type dendritic cells, suppress T cell proliferation via a nitric oxide-independent mechanism PLoS ONE 6 2011 e21893
69. N.R. Fortenbery, K.H. Paraiso, M. Taniguchi, C. Brooks, L. Ibrahim, and W.G. Kerr SHIP influences signals from CD48 and MHC class I ligands that regulate NK cell homeostasis, effector function, and repertoire formation J Immunol 184 2010 5065 5074